|Number of FTE:||441|
|Production capacity:||8 sterile filling lines, 4 lines for ampoules and vials covering format sizes from 1 mL to 100 mL|
|Competencies:||Sterile and aseptic filling|
Contract manufacturing of parenteral solutions and suspensions
Owing to our expertise in the field of contract manufacturing of parenteral liquids we are a respected business partner that makes an active contribution toward the success of our customers’ projects.
Services from a single source
hameln rds provides all services that are required to launch a product in the market from one single source.
With more than 60 years of experience, hameln pharma specializes in contract manufacturing of parenteral solutions and suspensions in ampoules and vials. In our GMP-certified state-of-the-art production plant in Hameln, more than 460 employees produce, test and package drugs for customers worldwide.
Anesthetics - Solutions - Solvents
Traditionally, one focus of our activity is on the production of demanding compounds such as anesthetics, inflammable and oxygen-sensitive liquids and chilled products. In general, we produce parenteral solutions and suspensions – aseptic or terminally sterilized – in glass containers.
For over 60 years, hameln pharma has been active in pharmaceutical contract manufacturing, which is considered the supreme discipline in drug production.
1950: Established by medical practitioner and pharmacist Günther Kerstein, the grandfather of the former company owner, production of own medicaments.
1970: Toward the end of the 1960s, when the original production facility had become too small for the fast growing company, the Kerstein family acquired land at a new location. In the new building erected here, improved technical plant was taken into operation. In the following years, the company specialized in the production of parenteral drugs.
Aseptic production of highly potent drugs such as anesthetics, combustible liquids, suspensions, oily solutions and chilled products represented the centerpiece of the company’s production.
1986: hameln pharma passed the FDA inspection, providing the company access to markets outside Europe.
2005: The company continued to develop: In order to focus stronger on the needs of contract-manufacturing customers, hameln rds (research and approval services for the health-care market) and hameln plus (worldwide sale of generic drugs for acute care) were spun off.
hameln pharma continued to consistently develop its strategy as a customer-oriented company. Today, hameln pharma is known as a specialist in contract manufacturing of parenteral solutions and suspensions differentiating itself from the competition by focusing on its core competencies of attention to detail, flexibility and reliability.
2014: The Siegfried Group acquired hameln pharma and hameln rds with effect from end November 2014, thereby expanding its value-added chain.
Langes Feld 13
Phone +49 5151 581 0